Advertisement

Antipsychotische Wirksamkeit des atypischen Neuroleptikums Amisulprid auf Positiv- und Negativsymptomatik

  • H.-J. Möller
Chapter

Zusammenfassung

Mit den modernen Antipsychotika verbinden sich große Hoffnungen hinsichtlich der Therapie schizophrener Erkrankungen: Die im Vergleich zu klassischen Neuroleptika bessere extrapyramidalmotorische Verträglichkeit und bessere Wirksamkeit auf die Negativsymptomatik sowie eventuell auch ausgeprägteren Effekte auf Depressivität und kognitive Störungen sollen zu einer günstigeren Beeinflussung des Krankheitsverlaufs und zu einer höheren Lebensqualität der Patienten führen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Adler G (2001) Amisulpride in patients with chronic schizophrenia: comparison with other atypical antipsychotics. World J Biol Psychiatry 2 (Suppl 1): 311SGoogle Scholar
  2. 2.
    Adler G, Weber D, Grieshaber S, Schmitt A, Dressing H (2000) Atypical antipsychotics and memory function in patients with chronic schizophrenia. Int J Neuropsychopharmacol 3 (Suppl 1): S165Google Scholar
  3. 3.
    Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E (2001) Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 21: 8–13PubMedCrossRefGoogle Scholar
  4. 4.
    Allison DB, Mentore JL, Heo M, Weiden PJ, Cappellerie J, Chandler LP (1997) Weight gain associated with conventional and newer antipsychotics. Poster, 151. APA, Toronto, CanadaGoogle Scholar
  5. 5.
    Bacher NM, Kaup BA (1996) Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am J Psychiatry 153: 137PubMedGoogle Scholar
  6. 6.
    Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68–72PubMedCrossRefGoogle Scholar
  7. 7.
    Carpenter Jr WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–452PubMedCrossRefGoogle Scholar
  8. 8.
    Carpenter WT (1991) Psychopathology and common sense. Biol Psychiatry 29: 735–737PubMedCrossRefGoogle Scholar
  9. 9.
    Carriere P, Bonhomme D, Lemperiere T (2000) Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: 321–329PubMedCrossRefGoogle Scholar
  10. 10.
    Chabannes JP, Pelissolo A, Farah S, Gerard D (1998) Evaluation de l’efficacite et de la tolerance de l’amisulpride dans le traitement des psychoses schizophreniques. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses]. Encephale 24: 386–392PubMedGoogle Scholar
  11. 11.
    Colonna L, Saleem P, Dondey-Nouvel L, Rein W (2000) Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 15: 13–22Google Scholar
  12. 12.
    Committee for Proprietary Medicinal Products [CPMP] (1998) Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia. The European Agency for the Evaluation of Medicinal Products, LondonGoogle Scholar
  13. 13.
    Conley RR, Kelly DL, Gale EA (1998) Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 33: 95–101PubMedCrossRefGoogle Scholar
  14. 14.
    Cooper SJ, Raniwalla J, Welch C (1996) A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Eur Neuropsychopharmacol 6 (Suppl 3): 148CrossRefGoogle Scholar
  15. 15.
    Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C (2000) A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 101: 218–225PubMedCrossRefGoogle Scholar
  16. 16.
    Costa-e-Silva JA (1990) A comparative double-blind trial of amisulpride versus haloperidol in the treatment of acute psychotic disorders [in French]. Ann Psychiatry 5 (1): 71–78Google Scholar
  17. 17.
    Coulouvrat C, Dondey-Nouvel L (1999) Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 14: 209–218PubMedCrossRefGoogle Scholar
  18. 18.
    Curran MP, Perry CM (2001) Amisulpride: a review of its use in the management of schizophrenia. Drugs 61: 2123–2150PubMedCrossRefGoogle Scholar
  19. 19.
    Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS (1996) Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 153: 417–419PubMedGoogle Scholar
  20. 20.
    Danion JM, Rein W, Fleurot O (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156: 610–616Google Scholar
  21. 21.
    Davis R, Markham A (1997) Ziprasidone. CNS Drugs 8 (2): 153–159CrossRefGoogle Scholar
  22. 22.
    Delcker A, Schoon ML, Oczkowski B, Gaertner HJ (1990) Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a double-blind study. Pharmacopsychiatry 23: 125–130PubMedCrossRefGoogle Scholar
  23. 23.
    Fleurot O, Martins S, Loo H, Peuskens J, Rein W (2002) Amisulpride vs olanzapine in schizophrenia. Preliminary results on short-term analysis. Eur Psychiatry 17 (Suppl 1): 107sCrossRefGoogle Scholar
  24. 24.
    Franz M, Gallhofer B (1997) Risperidon — ein neuer Serotonin-Dopamin-Antagonist zur Behandlung der Schizophrenie. Psychopharmakotherapie 2: 54–58Google Scholar
  25. 25.
    Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H (1996) Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6: 13–20Google Scholar
  26. 26.
    Henderson DC, Nasrallah RA, Goff DC (1998) Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 59: 585–588PubMedCrossRefGoogle Scholar
  27. 27.
    Kirkpatrick B, Kopelowicz A, Buchanan RW, Carpenter WT (2000) Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 22: 303–310PubMedCrossRefGoogle Scholar
  28. 28.
    Lecrubier Y, Benkert O, Kasper S et al. (2000) Amisulpride versus risperidone in schizophrenia: comparing clinical and functional outcome in a 6 month study [abstract no. 196]. 39th Annual Meeting of the American College of Neuropsychopharmacology, Dec 10–14 2000, San JuanGoogle Scholar
  29. 29.
    Lecrubier Y, Boyer P, Turjanski S, Rein W (1997) Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 43: 95–103Google Scholar
  30. 30.
    Lee MA, Thompson PA, Meltzer HY (1994) Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55 Suppl B: 82–87Google Scholar
  31. 31.
    Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual „Atypical“antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159: 180–190PubMedCrossRefGoogle Scholar
  32. 32.
    Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D (1998) Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 59: 521–527PubMedCrossRefGoogle Scholar
  33. 33.
    Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18–22PubMedCrossRefGoogle Scholar
  34. 34.
    Martin J, Gomez JC, Garcia BE, Cuesta M, Alvarez E, Gurpegui M (1997) Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J Clin Psychiatry 58: 479–483Google Scholar
  35. 35.
    Meats P (1997) Quetiapine („Seroquel“); an effective and well-tolerated atypical antipsychotic. Int J Psych Clin Prac 1: 231–239CrossRefGoogle Scholar
  36. 36.
    Meltzer HY (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3: 64–75PubMedGoogle Scholar
  37. 37.
    Meltzer HY, Lee MA, Ranjan R (1994) Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl 384: 95–101PubMedCrossRefGoogle Scholar
  38. 38.
    Mountjoy CQ, Baldacchino AM, Stubbs JH (1999) British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 156: 158–159PubMedGoogle Scholar
  39. 39.
    Möller HJ (2000) Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 71: 329–344PubMedCrossRefGoogle Scholar
  40. 40.
    Möller HJ (2001) Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur Arch Psychiatry Clin Neurosci 251: 217–224PubMedCrossRefGoogle Scholar
  41. 41.
    Möller HJ, Boyer P, Fleurot O, The PROD-ASLP Study Group (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with Haloperidol. Psychopharmacology 132: 396–401Google Scholar
  42. 42.
    Möller HJ, Müller H (1997) Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatry Clin Neurosci 247: 1–5PubMedCrossRefGoogle Scholar
  43. 43.
    Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenia patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245: 45–49Google Scholar
  44. 44.
    Möller HJ, Müller WE, Bandelow B (2001) Neuroleptika. Pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  45. 45.
    Möller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, Bentsen H, Eich FX, Farrow L, Fleischhacker WW, Gerlach J, Grafford K, Hentschel B, Hertkorn A, Heylen S, Lecrubier Y, Leonhard JP, McKenna P, Maier W, Pedersen V, Rappard A, Rein W, Ryan J, Sloth Nielsen M, Stieglitz RD, Wegener G, Wilson J (1994) Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology 115: 221–228Google Scholar
  46. 46.
    Müller N, Möller HJ (1999) Amisulprid in der Therapie schizophrener Negativsymptomatik. Psychopharmakotherapie 6 (Suppl 9): 15–19Google Scholar
  47. 47.
    Naber D, Lambert M, Krausz M (1999) Atypische Neuroleptika in der Behandlung schizophrener Psychosen. UNI-MED, BremenGoogle Scholar
  48. 48.
    Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) Dl, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444–1449PubMedGoogle Scholar
  49. 49.
    Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152: 130–134PubMedGoogle Scholar
  50. 50.
    Papp M, Wieronska J (2000) Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol 14: 46–52PubMedCrossRefGoogle Scholar
  51. 51.
    Peuskens J (2001) Efficacy of new antipsychotics on cognitive functions in schizophrenia. Eur Neuropsychopharmacol 11 (Suppl 3): S136 - S137CrossRefGoogle Scholar
  52. 52.
    Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W, Amisulpride study group (1999) Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 88: 107–117PubMedCrossRefGoogle Scholar
  53. 53.
    Pichot P, Boyer P (1988) A double-blind, controlled, multicenter trial of amisulpride versus high dose haloperidol in acute psychotic disorders [in French]. Ann Psychiatry 3 (3): 326–332Google Scholar
  54. 54.
    Puech A, Fleurot O, Rein W (1998) Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 98: 65–72Google Scholar
  55. 55.
    Reinbold H (2000) Gewichtszunahme unter Neuroleptika-Therapie. Psychopharmakotherapie 7: 15–17Google Scholar
  56. 56.
    Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57–73CrossRefGoogle Scholar
  57. 57.
    Sharma T, Mockler D (1998) The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18 (Suppl 1): 12S - 19SPubMedCrossRefGoogle Scholar
  58. 58.
    Smeraldi E (1998) Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord 48: 47–56PubMedCrossRefGoogle Scholar
  59. 59.
    Smith RC, Chua JW, Lipetsker B, Bhattacharyya A (1996) Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 57: 460–466PubMedCrossRefGoogle Scholar
  60. 60.
    Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Saf 22: 195–214PubMedCrossRefGoogle Scholar
  61. 61.
    Tanner TB, Ganguli R, Reddy R, Allen M, Field K (1995) Risperidone for treatment-refractory schizophrenia. Am J Psychiatry 152: 1233PubMedGoogle Scholar
  62. 62.
    Tollefson GD, Kuntz AJ (1999) Review of recent clinical studies with olanzapine. Br J Psychiatry 37 (Suppl): 30–35Google Scholar
  63. 63.
    Tollefson GD, Sanger TM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466–474PubMedGoogle Scholar
  64. 64.
    Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG (1998) Relation of serum anti-cholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry 59: 184–188PubMedCrossRefGoogle Scholar
  65. 65.
    Wehnert A, Mack R, Stilwell C, Rasmussen C, Silber C (1997) Direct Effect of Sertindole on the Primary Negative Symptoms of Schizophrenia: A PATH Analysis. Presented as Poster at the 6th World Congress of Biological Psychiatry, Nice, June 22–27Google Scholar
  66. 66.
    Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schroder J, Rein W, Benkert O (1998) Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology — a double-blind controlled study comparing a selective D2-like antagonist to a mixed Dl-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 137: 223–232Google Scholar
  67. 67.
    Wolfersdorf M, Konig F, Straub R (1994) Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptic zotepine and haloperidol. Neuropsychobiology 29: 189–193PubMedCrossRefGoogle Scholar
  68. 68.
    Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, The Sertindole Study Group (1997) Controlled, dose-response study of sertin-dole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–791Google Scholar
  69. 69.
    Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, Amisulprid Study Group (2002) Amisulpride vs. Risperidone in chronic schizophrenia: results of a 6-months double-blind study. Neuropsychopharmacology 27: 1071–1081PubMedCrossRefGoogle Scholar
  70. 70.
    Martin S, Loo H, Peuskens J, Thirumalai S, Gindicelli A, Fleurot O, Rein W (2002) A double-blind, randomised comparative trial of Amisulpride versus Olanzapine in the treatment of schizophrenia: short-term results at two months. Current Medical Research and Opinion 18: 355–362PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • H.-J. Möller

There are no affiliations available

Personalised recommendations